Insight Molecular Diagnostics Inc. (IMDX)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $60.87M
Last updated: Nov 17, 2026 at 4:10 PM ET
Insight Molecular Diagnostics Inc. (IMDX) Statistics
Insight Molecular Diagnostics (IMDX) has a market cap of $60.87M and an enterprise value of $51.25M. It kept -2137.33% of revenue as net income over the last 12 months. Its share count is up 15.08% from a year earlier.
Total Valuation
Enterprise value is 15.80% below the market cap, as cash exceeds debt.
| Market Cap | $60.87M |
|---|---|
| Enterprise Value | $51.25M |
| Latest price (Nov 17, 2026) | $1.78 |
Key Dates
The next earnings report is expected on Mar 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 16, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 33.3x. Its year-end P/S ranged from 19.3x to 131.8x from 2020 to 2025.
| P/S Ratio | 33.3x |
|---|---|
| Forward P/S | 63.0x |
Price Statistics
The stock is down 75.95% over 52 weeks and trades 44.38% below its 50-day average.
| Beta (1Y) | 2.64 |
|---|---|
| 52-Week Change | -75.95% |
| 1-Month Change | -38.41% |
| 3-Month Change | -59.36% |
| 6-Month Change | -67.99% |
| 5-Year Change | -95.49% |
| 10-Year Change | -96.35% |
| Total Return (1Y) | -75.95% |
| Total Return (3Y CAGR) | -24.21% |
| Total Return (5Y CAGR) | -49.96% |
| Return vs SPY (1Y) | -83.44% |
| Max Drawdown (1Y) | -76.27% |
| Max Drawdown (3Y) | -79.01% |
| Sharpe Ratio (1Y) | -1.19 |
| Correlation with SPY (1Y) | 0.34 |
| 50-Day Average | $3.20 |
| 200-Day Average | $4.48 |
| 52-Week Range | $1.85 to $7.51 |
| RSI (14 Days) | 20.7 |
| Average Volume (20 Days) | 203.63K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.46x current liabilities.
| Current Ratio | 1.46x |
|---|---|
| Quick Ratio | 1.42x |
| Interest Coverage | -488.35x |
Returns and Efficiency
Return on invested capital is 145.71% over the last 12 months, against a 5-year average of 134.91%.
| Return on Assets (ROA) | -193.56% |
|---|---|
| Return on Invested Capital (ROIC) | 145.71% |
| Return on Capital Employed (ROCE) | -343.43% |
| ROIC (5Y Average) | 134.91% |
| Asset Turnover | 0.06x |
| Inventory Turnover | 3.08x |
| Receivables Turnover | 5.53x |
| Cash Conversion Cycle | -814 days |
Scores
IMDX has an Altman Z-Score of -32.22, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -32.22 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $1.97M over the last 12 months is down 55.27% from the 12 months before.
| Revenue | $1.97M |
|---|---|
| Revenue Growth (YoY) | -55.27% |
| Gross Profit | $1.08M |
| Operating Income | -$42.93M |
| Pretax Income | -$42.08M |
| Net Income | -$42.08M |
| EBITDA | -$39.50M |
| EBIT | -$42.00M |
| Reported EPS (TTM) | -$1.26 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $11.02M |
|---|---|
| Total Debt | $1.41M |
| Net Cash | $9.62M |
| Net Cash Per Share | $0.26 |
| Working Capital | $4.37M |
| Shareholder Equity | -$24.18M |
| Total Assets | $21.74M |
| Total Liabilities | $45.92M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $3.71M of capital spending, operating cash flow left -$32.60M of free cash flow.
| Operating Cash Flow | -$28.89M |
|---|---|
| Capital Expenditures | $3.71M |
| Free Cash Flow | -$32.60M |
| FCF Per Share | -$1.00 |
| Depreciation and Amortization | $2.50M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -2180.09%.
| Gross Margin | 54.65% |
|---|---|
| Operating Margin | -2180.09% |
| Pretax Margin | -2137.33% |
| Net Margin | -2137.33% |
| EBITDA Margin | -2005.94% |
| EBIT Margin | -2132.96% |
| FCF Margin | -1655.51% |
| Gross Margin (5Y Average) | 37.24% |
Growth
Revenue grew 61.76% a year over 3 years.
| Revenue Growth (3Y CAGR) | +61.76% |
|---|---|
| Revenue Growth (5Y CAGR) | +27.24% |
Dividends and Yields
IMDX does not pay a dividend. Its free cash flow yield is -49.68%.
| FCF Yield | -49.68% |
|---|---|
| Buyback Yield | -37.56% |
| Shareholder Yield | -37.56% |
Stock Splits
The last split was a 1-for-20 reverse split on Jul 25, 2023.
| Last Split Date | Jul 25, 2023 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:20 |
Peer Position
Against 9 similar companies, IMDX has the 2nd highest P/S.
P/S RatioPeer median 2.4x
ROICPeer median -23.27%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +17.54%
| P/S Ratio | 33.3x vs 2.4x median |
|---|---|
| ROIC | 145.71% vs -23.27% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -55.27% vs +17.54% median |
Analyst Forecast
Consensus estimates put revenue growth at 28.18% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +28.18% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About IMDX
What is IMDX's market cap?
Insight Molecular Diagnostics has a market cap of $60.87M. Its enterprise value, which adds debt and subtracts cash, is $51.25M.
How many shares of IMDX are outstanding?
Insight Molecular Diagnostics has 36.86M shares outstanding. The count is up 15.08% from a year earlier.
Does IMDX pay a dividend?
No. Insight Molecular Diagnostics does not pay a dividend.
How much debt does IMDX have?
Insight Molecular Diagnostics has $1.41M of total debt and $11.02M of cash and equivalents, a net cash position of $9.62M.
IMDX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors